Combination therapy for KRAS G12C mutated colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug combination (IBI351, cetuximab, and FOLFIRI) as first treatment or as a second treatment after standard chemotherapy for people with KRAS G12C mutated colorectal cancer that has spread. The goal is to see if it works well and is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have colorectal cancer that has spread to other parts of the body (stage IV).
- A special test must show your cancer has a specific mutation called KRAS G12C.
- You can join either as a first treatment or after your cancer has worsened on standard chemotherapy.
- You must be able to take oral medication and have normal organ function (like liver, kidney, blood).
- You must not have certain other cancers or unstable brain metastases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (irinotecan liposomes, cetuximab, and vemurafenib) for people with advanced colorectal cancer that has a specific genetic change (BRAF V600E mutation) and did not respond to first treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests a combination of two targeted drugs (panitumumab and sotorasib) with a common IV chemo (5-fluorouracil) as a first treatment for people with a specific type of advanced colorectal cancer who cannot tolerate stronger chemo. It offers a gentler option that may be more effective than standard care.
This trial tests a combination of two drugs—cetuximab or bevacizumab plus a chemotherapy pill (trifluridine/tipiracil)—for people with metastatic colorectal cancer that has no RAS or BRAF mutations. It's for patients whose cancer grew after first responding to cetuximab, and who have had other treatments since then.
This trial tests whether giving a targeted drug (cetuximab) with chemotherapy continuously or on breaks works better as a first treatment for people with a specific type of colorectal cancer that has spread (RAS/BRAF wild-type). The goal is to find a way to maintain control of the cancer with fewer side effects.
This trial tests a combination of two drugs (fulzerasib and cetuximab) given before surgery to shrink locally advanced colorectal cancer that has a specific genetic mutation called KRAS G12C. The goal is to help make the cancer easier to remove surgically and improve outcomes.
This trial tests a combination of four drugs (irinotecan liposome, fluorouracil, folinic acid, vermofenib, and cetuximab) as a first treatment for people with advanced colorectal cancer that has a specific BRAF V600E mutation. It aims to see if this combination can shrink tumors or slow their growth.
Hear when a new KRAS G12C Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.